[Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors]

Chun-yu Zhang, Zhang CY, Hong-yan Guo, Guo HY, Li H, Hua Li, Hong-wu Wen, Wen HW, Liang XD, Xu-dong Liang, Qiao J, Jie Qiao
Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2012 · doi:10.3760/cma.j.issn.0253-3766.2012.09.010 · PMID:23159083
other public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

Ovarian clear cell adenocarcinoma patients presented younger, with higher endometriosis comorbidity and earlier stage disease, but showed increased drug resistance and poorer prognosis, especially in advanced stages.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-03 · read from full text ⓘ

This study compared 47 patients with ovarian clear cell adenocarcinoma (OCCA) to 53 patients with ovarian serous cyst adenocarcinoma, analyzing clinical characteristics, drug resistance features, and prognostic factors using clinical and follow-up data. OCCA patients had a younger onset age, higher rates of elevated CA125, higher comorbidity with endometriosis, and a much higher proportion of early-stage disease than the serous group; while overall drug resistance rates were similar between OCCA and serous cancers, drug resistance was markedly higher in advanced-stage OCCA than in advanced-stage serous cancer, and OCCA advanced-stage patients had shorter median overall survival. The authors identified OCCA histology and advanced stage as independent risk factors for drug resistance, and multiple factors including OCCA, advanced stage, suboptimal surgery, fewer than 6 chemotherapy cycles, and chemotherapy resistance as independent risk factors for overall survival, with the explicit limitation that the analysis was based on relatively small cohorts. Relevance to endometriosis: endometriosis (EMS) was reported as much more common in OCCA (46.8%) than in the serous control group (7.5%), though the paper’s main focus is clinical features, drug resistance, and prognostic factors in OCCA rather than mechanistic endometriosis biology.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To investigate the clinical features and factors involved in the drug resistance and prognosis of ovarian clear cell adenocarcinoma (OCCA). METHODS: Forty-seven OCCA patients and 53 ovarian serous cyst adenocarcinoma (OSCA) patients were included in this study. Their clinical characteristics, drug resistance, and prognostic factors were analyzed. RESULTS: The onset age of OCCA was (49.09 + 11.80) years old, and that of OSCA was (55.51 + 1.38) year old. There were 53.3% (24/45) of OCCA and 98.0% (50/51) of OSCA patients who had elevated CA125 levels. There were 46.8% (22/47) of OCCA patients and 7.5% (4/53) of OSCA patients who suffered from endometriosis (EMS). The percentage of early stage (stage I and stage II) OCCA was 80.9% (38/47), and that of OSCA was 11.3% (6/53). A statistically significant difference was observed on all these aspects (P < 0.05). The percentage of drug resistant OCCA was 26.1% (12/46), and that of OSCA was 24.0% (12/50), with a non-significant difference (P = 0.814).Among the patients with advanced stage disease, the percentage of drug resistance was 87.5% (7/8) for OCCA, while that of OSCA was 25.0% (11/44), showing a statistically significant difference (P = 0.003). Multiple logistic regression analysis revealed that OCCA (OR = 21.774, 95%CI: 2.438 to 194.431) and advanced stage (OR = 58.329, 95%CI: 5.750 to 591.703) were independent risk factors of drug resistance in ovarian epithelial cancers. For the advanced stage patients, the median overall survival time of OCCA and OSCA were 11 and 29 months, respectively, with a statistically significant difference (P = 0.000). Cox survival analysis showed that OCCA, advanced stage, suboptimal surgery, fewer than 6 cycles of chemotherapy and drug resistance were all risk factors of OS in ovarian cancer patients (P < 0.05). CONCLUSIONS: The age of onset in OCCA patients is younger than that of OSCA patients. The proportion of combination with endometriosis (EMS) is higher, and more early stage disease is observed in OCCA patients. The percentage of drug resistant in OCCA is higher, especially in advanced stage patients. The prognosis of advanced stage OCCA patients is poorer than that of OSCA patients in advanced stage.
Full text 3,157 characters · extracted from oa-doi-fallback · click to expand
卵巢透明细胞癌的临床特点耐药特征和预后因素分析 Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors 摘要目的 探讨卵巢透明细胞癌的临床特点和耐药特征,并分析影响预后的相关因索.方法 收集47例卵巢透明细胞癌患者的临床和随访资料,分析其临床特点、耐药特征和预后影响因素.以同期收治的53例卵巢浆液性腺癌患者作为对照.结果 卵巢透明细胞癌和卵巢浆液性腺癌患者的发病年龄分别为(49.09±11.80)岁和(55.51±1.38)岁,其中血CA125升高者分别占53.3％(24/45)和98.0％ (50/51),合并子宫内膜异位症者分别占46.8％(22/47)和7.5％(4/53),早期(Ⅰ、Ⅱ期)患者所占的比例分别为80.9％ (38/47)和11.3％ (6/53),差异均有统计学意义(均P＜0.05).卵巢透明细胞癌和卵巢浆液性腺癌患者的耐药率分别为26.1％ (12/46)和24.0％(12/50),差异无统计学意义(P=0.814)；但晚期卵巢透明细胞癌患者的耐药率(87.5％)明显高于卵巢浆液性腺癌(25.0％,P=0.003).卵巢透明细胞癌(OR=21.774,95％ CI为2.438 ～194.431)以及分期晚(OR=58.329,95％ CI为5.750 ～591.703)是与卵巢上皮性癌耐药密切相关的独立危险因素.晚期卵巢透明细胞癌与卵巢浆液性腺癌患者的中位生存时间(OS)分别为11和29个月,差异有统计学意义(P＜0.001).病理类型为卵巢透明细胞癌、肿瘤晚期、手术不满意、化疗＜6个疗程以及化疗耐药是与卵巢上皮性癌患者OS密切相关的独立危险因素(均P＜0.05).结论 与卵巢浆液性腺癌相比,卵巢透明细胞癌患者的发病年龄早,多合并子宫内膜异位症,早期患者所占的比例较高；但卵巢透明细胞癌易发生耐药,在晚期患者中更明显,预后更差. 更多相关知识 abstractsObjective To investigate the clinical features and factors involved in the drug resistance and prognosis of ovarian clear cell adenocarcinoma (OCCA).Methods Forty-seven OCCA patients and 53 ovarian serous cyst adenocarcinoma (OSCA) patients were included in this study.Their clinical characteristics,drug resistance,and prognostic factors were analyzed.Results The onset age of OCCA was (49.09 + 11.80) years old,and that of OSCA was (55.51 + 1.38) year old.There were 53.3％ (24/45)of OCCA and 98.0％ (50/51) of OSCA patients who had elevated CA125 levels.There were 46.8％ (22/47)of OCCA patients and 7.5％ (4/53) of OSCA patients who suffered from endometriosis (EMS).The percentage of early stage (stage Ⅰ and stage Ⅱ) OCCA was 80.9％ (38/47),and that of OSCA was 11.3％ (6/53).A statistically significant difference was observed on all these aspects (P ＜ 0.05).The percentage of drug resistant OCCA was 26.1％ (12/46),and that of OSCA was 24.0％ (12/50),with a non-significant difference (P =0.814).Among the patients with advanced stage disease,the percentage of drug resistance was 87.5％ (7/8) for OCCA,while that of OSCA was 25.0％ (11/44),showing a statistically significant difference (P =0.003).Multiple logistic regression analysis revealed that OCCA (OR=21.774,95％CI:2.438 to 194.431) and advanced stage (OR =58.329,95％CI:5.750 to 591.703)were independent risk factors of drug resistance in ovarian epithelial cancers.For the advanced stage patients,the median overall survival time of OCCA and OSCA were 11 and 29 months,respectively,with a statistically significant difference (P =0.000).Cox survival analysis showed that OCCA,advanced stage,suboptimal surgery,fewer than 6 cycles of chemotherapy and drug resistance were all risk factors of OS in ovarian cancer patients (P ＜0.05).Conclusions The age of onset in OCCA patients is younger than that of OSCA patients.The proportion of combination with endometriosis (EMS) is higher,and more early stage disease is observed in OCCA patients.The percentage of drug resistant in OCCA is higher,especially in advanced stage patients.The prognosis of advanced stage OCCA patients is poorer than that of OSCA patients in advanced stage. More相关知识 - 浏览848 - 被引11 - 下载256 相似文献 - 中文期刊 - 外文期刊 - 学位论文 - 会议论文

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Drug Resistance, Neoplasm Ovarian Neoplasms Ovarian Neoplasms Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adult CA-125 Antigen CA-125 Antigen Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Cystadenocarcinoma, Serous Endometriosis Endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-08-01T06:07:04.264727+00:00
pubmed
last seen: 2026-05-13T22:15:58.344756+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine